

Quality of life (QOL) assessment in the care of individual cancer patients

Submission date 29/04/2010	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 29/04/2010	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 16/10/2015	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mrs Lyndsay Campbell

Contact details
Psychosocial and Clinical Practice Research Group
St. James Institute of Oncology
Level 3, Bexley Wing
Leeds
United Kingdom
LS9 7TF

Additional identifiers

Protocol serial number
1460

Study information

Scientific Title
Quality of life (QOL) assessment in the care of individual cancer patients: a randomised interventional trial

Acronym

ATT (Attention Control Study)

Study objectives

To test the hypothesis that regular completion of quality of life (QOL) questionnaire, without feeding back results to oncologists, can help patients to explain their problems and can result in improved well being. The secondary aim of the study is to obtain a pure control and attention-control group for future studies, in which the oncologists will have the QOL information and can potentially influence the measured outcomes.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Leeds East Research Ethics Committee approved on the 09/03/2004 (ref: 04/008)

Primary study design

Interventional

Study design

Randomised interventional process of care trial

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: All Cancers/Misc Sites; Disease: All

Interventions

After the baseline visit, patients in the intervention group will be asked to complete the EORTC QLQ-C30 and HADS on a touch-screen (TS) computer while waiting to see a doctor. This will be done over 3 consecutive visits. The results will be printed and filed, but not given to their oncologists. The control group will receive their usual medical care. All consultations will be audio-taped and subjected to content analysis.

Follow up length: 6 months

Study entry: single randomisation only

Intervention Type

Other

Phase

Phase III

Primary outcome(s)

1. Content of communication, measured at baseline and for a further three visits
2. Functional Assessment of Cancer Therapy General Scale (FACT-G), measured at baseline and at the end of the study

Key secondary outcome(s)

1. Other process measures (symptomatic drugs, tests, referrals), collected at baseline and for the next three visits

2. Patient-related outcomes (continuity of care and patient satisfaction), collected at baseline and at the end of the study
3. Descriptive information on patient views and attitudes regarding regular QOL data collection, collected at the end of the study

Completion date

30/11/2006

Eligibility

Key inclusion criteria

1. Newly diagnosed or relapsed patients with cancer starting chemotherapy or multimodality treatment
2. Expected to attend the clinic at least 3 times after the initial baseline visit;
3. Able and willing to give informed consent
4. Not taking part in other QL studies run by the Unit
5. Able to read and understand English
6. Not exhibiting overt psychopathology or serious cognitive dysfunction which would impede their being able to take part in the study
7. Either sex, lower age limit of 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

Does not meet the exclusion criteria

Date of first enrolment

01/03/2004

Date of final enrolment

30/11/2006

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Psychosocial and Clinical Practice Research Group
Leeds
United Kingdom
LS9 7TF

Sponsor information

Organisation
University of Leeds (UK)

ROR
<https://ror.org/024mrxd33>

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK (CRUK) (UK)

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary